CJC/IPA – No DAC

CJC-1295 / IPAMORELIN BLEND

Type: Dual-peptide research formulation

Description:
The CJC-1295 / Ipamorelin blend is a combined synthetic peptide formulation developed for laboratory research involving growth hormone signaling pathways, receptor interaction modeling, and endocrine communication dynamics. This formulation pairs a growth hormone–releasing hormone (GHRH) analog with a ghrelin receptor agonist, allowing researchers to examine coordinated receptor engagement within controlled experimental systems.

In research and preclinical models, this blend is commonly utilized to study pulsatile signaling behavior, receptor pathway integration, and peptide–peptide interaction effects within growth hormone regulatory networks. The complementary mechanisms of the two peptides make this formulation useful for investigating signal amplification, pathway timing, and structure–activity relationships in endocrine research environments.

Research Areas of Interest:

• Growth hormone signaling pathway research

• GHRH and ghrelin receptor interaction studies

• Endocrine communication modeling

• Peptide–peptide interaction and synergy analysis

• Signal timing and pathway integration research

Composition:

• CJC-1295: 5 mg

• Ipamorelin: 5 mg